Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck to pay $688 million to settle Enhance lawsuits

02/14/2013 | 11:35am EDT
A view of the Merck & Co. campus in Linden, New Jersey

(Reuters) - Merck & Co has agreed to pay $688 million to settle two U.S. class-action lawsuits by shareholders who said they lost money because the company concealed the poor results of a clinical trial of the anti-cholesterol drug Vytorin.

The federal lawsuits, led by several pension funds, alleged that Merck and Schering-Plough Corp knew more than a year in advance that the trial, known as Enhance, was a failure, but withheld that information from investors.

Shares of Merck fell nearly 15 percent and Schering fell nearly 21 percent on March 31, 2008, the first trading day after full trial results were released at the American Conference of Cardiology in Chicago. The companies merged in November 2009.

Law firms representing some of the plaintiffs said the combined settlements are among the 10 largest in a securities class-action that did not involve a restatement of financial results.

Christopher McDonald, a partner at Labaton Sucharow representing Schering investors, in a telephone interview said the settlements allow a "significant recovery" for shareholders.

He said that while the federal government has been successful in pursuing large fraud cases against some pharmaceutical companies, "it hasn't translated into any significant uptick in settlements of securities cases."

Merck, based in Whitehouse Station, New Jersey, said it has recorded a $493 million after-tax charge for the settlements, reducing the company's previously reported profit per share for the 2012 fourth quarter to 30 cents from 46 cents.

Bruce Kuhlik, Merck's general counsel, in a statement said the settlements avoid the uncertainties of a jury trial, which had been scheduled to begin March 4.

Merck also said it believes both companies acted responsibly in connection with the Enhance trial, and that the settlements include no admission of liability or wrongdoing.

"There's probably some merit (to the claims) or they wouldn't have settled for such a large amount," Judson Clark, a health care analyst with Edward Jones, said in a telephone interview. He has a "buy" rating on Merck.

Shares of Merck fell 26 cents to $40.89 in morning trading on the New York Stock Exchange.


The Enhance trial had sought to demonstrate that Vytorin, a combination drug marketed by Merck and Schering, was more effective than a competing drug in combating atherosclerosis, the buildup of plaque in artery walls.

But the companies announced in January 2008 that Vytorin did not stop plaque any better than an inexpensive statin, Zocor, in high-risk patients with an inherited form of heart disease, though it did significantly reduce cholesterol levels.

Two months later, in announcing full results of the Enhance trial at the Chicago conference, a panel of doctors urged patients to try older cholesterol drugs before Vytorin and Zetia, which Merck and Schering also sold jointly.

Vytorin pairs Zetia with the active ingredient of Zocor. Zetia helps block absorption of "bad" LDL cholesterol in the intestines, and Zocor helps block production by the liver of LDL cholesterol.

Zetia sales totaled $2.57 billion and Vytorin sales totaled $1.75 billion in 2012. Combined sales have fallen 17 percent since 2007, before the Enhance trial results were released. Merck posted total sales of $47.27 billion for 2012.


Merck said it will pay $215 million to settle a lawsuit brought by investors in its securities, and $473 million to settle a lawsuit by Schering investors.

The class period runs from December 6, 2006, through March 28, 2008, for Merck investors, and from January 3, 2007, to March 28, 2008, for Schering investors, court papers show.

Both settlements require approval by U.S. District Judge Dennis Cavanaugh in Newark, New Jersey. He certified both classes of investors in September.

Settlement papers were not immediately available, and it was unclear how much was being set aside to cover legal fees.

Lead plaintiffs in the Merck case include the Netherlands' Stichting Pensioenfonds ABP, Luxembourg's International Fund Management SA, the Jacksonville Police and Fire Retirement System in Florida, and the General Retirement System of the City of Detroit.

Lead plaintiffs in the Schering case included the Arkansas Teacher Retirement System, the Louisiana Municipal Police Employees' Retirement System, Massachusetts Pension Reserves Investment Management Board, and the Public Employees' Retirement System of Mississippi, court papers show.

The law firms Bernstein Litowitz Berger & Grossmann and Grant & Eisenhofer represent the Merck class. Bernstein Litowitz and Labaton Sucharow represent the Schering class.

The cases are In re: Schering-Plough Corp/Enhance Securities Litigation, U.S. District Court, District of New Jersey, No. 08-00397; and In re: Merck & Co Inc Vytorin/Zetia Securities Litigation in the same court, No. 08-02177.

(Reporting by Jonathan Stempel in New York; Additional reporting by Ransdell Pierson in New York; Editing by Jim Marshall and John Wallace)

By Jonathan Stempel

© Reuters 2013
Stocks mentioned in the article
ChangeLast1st jan.
MCDONALD'S CORPORATION 1.80% 242.96 Delayed Quote.11.23%
MERCK & CO., INC. 1.32% 77.54 Delayed Quote.-5.21%
THE LEAD CO., INC. -0.15% 662 End-of-day quote.-21.19%
All news about MERCK & CO., INC.
07/23MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combinat..
07/22ADAGENE : Agrees With Merck on Trials of Its Monoclonal Antibodies With Keytruda..
07/22MERCK : Eisai Win US FDA Approval of Keytruda Plus Lenvima Combination for Certa..
07/22MERCK : FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combin..
07/22FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® Combination for Patients..
07/21MERCK : Teams up with Noxxon to Evaluate NOX-A12 in Combination With Keytruda in..
07/21NOXXON Pharma N.V. Enters Second Clinical Collaboration with Merck & Co., Inc..
07/21BAYER : Heart Failure Treatment Wins EU Market Authorization
07/21MERCK : Secures European Approval for Verquvo for Chronic Heart Failure
07/21MERCK : VERQUVO® (vericiguat) Approved in the European Union
More news
Financials (USD)
Sales 2021 46 551 M - -
Net income 2021 12 867 M - -
Net Debt 2021 11 752 M - -
P/E ratio 2021 16,5x
Yield 2021 3,37%
Capitalization 196 B 196 B -
EV / Sales 2021 4,47x
EV / Sales 2022 4,06x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 77,54 $
Average target price 94,10 $
Spread / Average Target 21,4%
EPS Revisions
Managers and Directors
Kenneth C. Frazier Chairman & Chief Executive Officer
Robert M. Davis President
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-5.21%195 475
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
NOVARTIS AG1.10%207 246